Global Retirement Partners LLC Invests $448,000 in Exact Sciences Corporation $EXAS

Global Retirement Partners LLC bought a new position in Exact Sciences Corporation (NASDAQ:EXAS) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 8,434 shares of the medical research company’s stock, valued at approximately $448,000.

Several other institutional investors have also added to or reduced their stakes in the company. National Pension Service raised its holdings in shares of Exact Sciences by 75.1% during the 1st quarter. National Pension Service now owns 681 shares of the medical research company’s stock worth $29,000 after acquiring an additional 292 shares in the last quarter. SVB Wealth LLC purchased a new position in shares of Exact Sciences in the first quarter valued at $30,000. True Wealth Design LLC increased its position in Exact Sciences by 951.8% in the second quarter. True Wealth Design LLC now owns 589 shares of the medical research company’s stock worth $31,000 after purchasing an additional 533 shares during the last quarter. Banque Cantonale Vaudoise purchased a new stake in Exact Sciences during the first quarter valued at $34,000. Finally, Bessemer Group Inc. raised its stake in Exact Sciences by 1,980.6% during the second quarter. Bessemer Group Inc. now owns 645 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 614 shares in the last quarter. Hedge funds and other institutional investors own 88.82% of the company’s stock.

Insider Transactions at Exact Sciences

In other news, EVP Jacob A. Orville sold 5,000 shares of the business’s stock in a transaction on Wednesday, November 19th. The shares were sold at an average price of $75.00, for a total transaction of $375,000.00. Following the completion of the sale, the executive vice president directly owned 23,237 shares of the company’s stock, valued at approximately $1,742,775. The trade was a 17.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director James Edward Doyle sold 2,000 shares of the company’s stock in a transaction dated Thursday, October 9th. The stock was sold at an average price of $60.00, for a total transaction of $120,000.00. Following the completion of the transaction, the director owned 57,962 shares in the company, valued at approximately $3,477,720. The trade was a 3.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 9,858 shares of company stock worth $695,289. 1.20% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

EXAS has been the topic of a number of research reports. Evercore ISI boosted their target price on shares of Exact Sciences from $64.00 to $68.00 and gave the stock an “outperform” rating in a report on Tuesday, October 7th. Baird R W lowered Exact Sciences from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 20th. Benchmark downgraded Exact Sciences from a “buy” rating to a “hold” rating in a research report on Monday, November 24th. Zacks Research raised Exact Sciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 6th. Finally, Wells Fargo & Company reissued an “equal weight” rating and set a $105.00 target price (up previously from $85.00) on shares of Exact Sciences in a research report on Thursday, November 20th. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, eighteen have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $85.00.

Exact Sciences Stock Down 0.1%

Shares of NASDAQ:EXAS opened at $101.35 on Friday. The firm has a market capitalization of $19.20 billion, a PE ratio of -18.66, a price-to-earnings-growth ratio of 5.56 and a beta of 1.34. The business has a 50 day simple moving average of $67.66 and a two-hundred day simple moving average of $57.14. Exact Sciences Corporation has a 1 year low of $38.81 and a 1 year high of $101.87. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.89 and a quick ratio of 2.56.

Exact Sciences (NASDAQ:EXAS) last issued its quarterly earnings results on Monday, November 3rd. The medical research company reported $0.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.11. Exact Sciences had a negative return on equity of 1.75% and a negative net margin of 34.19%.The firm had revenue of $850.74 million during the quarter, compared to analyst estimates of $810.42 million. During the same period last year, the company earned ($0.21) EPS. Exact Sciences’s quarterly revenue was up 20.0% compared to the same quarter last year. Exact Sciences has set its FY 2025 guidance at EPS. On average, equities analysts predict that Exact Sciences Corporation will post -0.58 EPS for the current year.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.